Osteotech Inc

Osteotech — Merger or Acquisition (August 2010)

53 slides from Osteotech's merger presentation, Aug 17, 2010

  1. Slide 1: Employee Communication August 17, 2010

    Employee Communication August 17, 2010

  2. Slide 2: Neighbors Helping Neighbors Food Drive

    industrial way corridor neighbors helping neighbors FOOD DRIVE

  3. Slide 3: From Tissue Processor to Biologics Innovator

    From Tissue Processor to Biologics Innovator 1986 1991 2000 2005 2007 2009 2010 2011

  4. Slide 4: Traditional Allograft Bone and Soft Tissue

    traditional allograft BONE AND SOFT

  5. Slide 5: Grafton Demineralized Bone Matrix (DBM)

    grafton demineralized Bone Matrix (DBM) The Gold Standard in DBM

  6. Slide 6: Graftech Structural Allografts

    GRAFTECH STRUCTURAL ALLOGRAFTS

  7. Slide 7: Exclusive Technology

    Exausive Technology OF WhosteqtecH: 15 Months Post Op PROCEDURE “Dod

  8. Slide 8: Exssive Techrology

    Exssive Techrology ar OSTEOTECH"

  9. Slide 9: Exausive Toctrology OF

    Exausive Toctrology OF OSTEOTECH:* ili

  10. Slide 10: MagniFuse Bone Graft

    MagniPuse a MagniFuse’ BONE GRAFT MagniPuse: 3 ge 4 Mosrearec. > MagntPuse

  11. Slide 11: Facet

    FACET

  12. Slide 12: ar OSTEOTECH"

    ar OSTEOTECH"

  13. Slide 13: Grafton in Spine

    iosrea7EcH: » GRAFTON?’ in Spine gration 4 ns

  14. Slide 14: Grafton Matrix — Posterior Lumbar

    GRAFTON ® Matrix — Posterior Lumbar 1 Year Post Op

  15. Slide 15: Grafton Matrix Strips — Spinal Deformity

    GRAFTON ® Matrix Strips — Spinal Deformity

  16. Slide 16: Grafton A-Flex — Acetabular Revision

    GRAFTON ® A-Flex — Acetabular Revision Immediate Post Op 6 Months Post Op

  17. Slide 17: Grafton Flex

    ar OSTEOTECH" GRAFTON*® Flex

  18. Slide 18: Grafton Gel — Percutaneous Injection

    GRAFTON ® Gel — Percutaneous Injection

  19. Slide 19: Exclusive Technology

    Exasive Technology OF Whosteqrecr:

  20. Slide 20: Plexur P Wedge

    Plexur P ® Wedge Pre Op 8 Weeks Resumed Normal Activity

  21. Slide 21: Plexur P Block

    Plexur P ® Block Pre Op 3 Months Resumed Normal Activity

  22. Slide 22: Plexur P Cylinder

    Plexur P ® Cylinder Pre Op 3 Months Resumed Normal Activity

  23. Slide 23: Time — Rabbit, Months — Rabbit

    Time 0 — Rabbit 6 Months — Rabbit

  24. Slide 24: Exclusive Technology

    Excuse Technology OF Whosteqtecr PROCEDURE "Dod

  25. Slide 25: Plexur M — Shatzker VI

    Plexur M ® — Shatzker VI Pre Op Immediate Post Op 10 Months Post Op

  26. Slide 26: Plexur M — Proximal Tibial Tumor

    Plexur M ® — Proximal Tibial Tumor 44 Weeks Post Op 21 Weeks Post Op 7 Weeks Post Op Immediate Post Op

  27. Slide 27: Injectable Non-weight Bearing Polyurethane Platform

    Injectable Non-weight bearing Polyurethane platformPart A: Lysine triisocyanate-polyethylene glycol (LTI-PEG)Part B: Hardener (Polyol + catalyst) Setting time: 15 minutes Bone In situ Bone/polymer foam Setting time: 15 minutes Handling time: 3-5 minutes In situ Bone/polymer foam

  28. Slide 28: MagniFuse

    ;OTECHE* Magnituse- aoe ea MagniFuse it f=2) . 4 ‘ BONE GRAFT \g ahr ¥ > MagniPuse wie MagniPuse Ps A &

  29. Slide 29: Growth Factors in Natural Human Collagen

    Growth Factors Full Array of Growth Factors Embedded in Natural Human Collagen • BMP 2,4,6,7 • TGF-? • PDGF • IGF Nanotechnology

  30. Slide 30: MagniFuse Cervical & Thoracic

    MagniFuse ® Cervical & Thoracic

  31. Slide 31: MagniFuse PL: Rapid and Solid Bone Formation

    MagniFuse ® PL 3 Months Post Op 6 Months Post Op Rapid and Solid Bone Formation

  32. Slide 32: Rapid and Solid Bone Formation

    Immediate Post Op 3 Months Post Op 6 Months Post Op Rapid and Solid Bone Formation

  33. Slide 33: 6-Months Post Op (3-Dimensional CT Reconstruction)

    6-Months Post Op (3-Dimensional CT Reconstruction)

  34. Slide 34: MagniFuse

    Whosteo7ecH: << MagniFuse

  35. Slide 35: Se

    Se

  36. Slide 36: ar OSTEOTECH"

    ar OSTEOTECH"

  37. Slide 37: Microstructure 250x 1,000x 10,000x

    Microstructure 250x 1,000x 10,000x

  38. Slide 38: HCT Human Collagen Technology and Product Portfolio

    HCT™ Human Collagen Technology MagniFuse ® Bone Graft FacetLinx™ Fusion Technology Plexur ® Innovative Grafting Grafton ® Demineralized Bone Matrix Xpanse ® Bone Insert Exhibit F:

  39. Slide 39: Medtronic: Innovating for Life Town Hall Meeting

    Medtronic: Innovating for Life Town Hall Meeting August 17, 2010 1 | MDT Confidential

  40. Slide 40: The Early Years

    The Early Years

  41. Slide 41: The Place to Be ... A Rich History of Leadership

    The Place to Be ... A Rich History of Leadership 50 ~50 21,000+ Diseases Treated Years of the Patents Awarded with Medtronic Medtronic Mission Products 7M 150,000+ $11B Patients Benefit fit Returned to from Medtronic Products Shareholders Products in Last 5 Years Annually

  42. Slide 42: Innovation Has Driven Growth and Success

    Innovation Has Driven Growth and Success Driven FY01 FY10 CRDM CardioVascular cular $ Billions lllioi nss 15.8 16 14.6 Physio Control 13.5 12.3 12 11.3 10.1 Spinal 9.1 8 7.7 6.4 5.6 Neuromodulation 4 Diabetes 0 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 Surgical Tech

  43. Slide 43: Global Diversification has Driven Performance

    Global Diversification has Driven Performance Europe & FY01 Central Asia Japan International Revenue Int’l Greater China % of Total Revenue 8 40% $ Billions Other Asia 6.5 6 5.6 5.2 4.4 Canada 4 3.7 30% 3.3 2.9 Middle East 2.3 1.9 1.9 & Africa 2 Latin America 0 20% FY01 FY02 FY03 FY04 FY05 FY06 FY07

  44. Slide 44: Leading Positions in Chronic Disease Markets

    Leading Positions in Chronic Disease Markets Chronic Disease Epidemic: Focus Positions Us for Growth Large, Growing and Costly 60% of deaths worldwide from chronic disease 17% growth in chronic disease deaths by 2015 of healthcare spending 75% on chronic disease

  45. Slide 45: Integrating Technology to Deliver Innovation

    Integrating Technology to Deliver Innovation LIFE SCIENCES Targeted Drug Delivery Materials ENGINEERING SCIENCES Power Sources Closed-Loop Systems Miniaturization INFORMATION Connected Care Imaging TECHNOLOGY Navigation

  46. Slide 46: We Share a Patient-Centric Mission

    We Share a Patient-Centric Mission “We believe our first responsibility is to use technology to enhance the gift of life; to develop therapy-driven products that alleviate pain and promote biological healing and restore function.”

  47. Slide 47: Together, We Will Be Better Positioned To

    Together, We Will Be Better Positioned To: Drive awareness and demand for Biologics Offer distinctive product portfolio and pipeline Create opportunities to develop breakthrough next-generation products Expand across treatment areas Accelerate growth internationally With our shared expertise, innova

  48. Slide 48: Medtronic Therapy Portfolio

    Medtronic Therapy Portfolio Growth Factors DBMs Synthetics Grafting INFUSE ® PROGENIX ® MASTERGRAFT ® Bone Structural Specialty Traditional CAPSTONE ® Cortical Facet Dowel Allograft Bone Chips Allograft CORNERSTONE ® Durepair ® PRECISION ®

  49. Slide 49: Therapy Portfolio with Osteotech

    Therapy Portfolio Osteotech Growth Factors DBMs Synthetics Grafting INFUSE ® GRAFTON ® MASTERGRAFT ® MAGNIFUSE ® PLEXUR ® Bone PROGENIX ® Structural Specialty Traditional CAPSTONE ® BioGenesis ® Allograft Bone Chips Allograft CORNERSTONE ® Cortical Facet Dowel Trad’l Allograft Graftech ® Durepair ®

  50. Slide 50: Medtronic Biologics & Regenerative Therapies

    Medtronic Biologics & Regenerative Therapies Distinctive Capabilities Global Revenue $ Millions World-class Biologics talent +37% 871 806 833 Gold-standard 701 commercial capabilities 571 Drug/device combo 413 product development 257 expertise 95 Industry-leading clinical and economic evidence FY03

  51. Slide 51: Upside Remains in rhBMP-2 Franchise

    Upside Remains in rhBMP-2 Franchise, and We Are Investing to Unlock New Applications Dental/CMF Current indications Sinus Aug. / Alveolar Cleft Ext. Sockets Ongoing studies New/projected studies Ridge Augmentation Multi-level ACDF 8 anticipated IDEs Cervical (ACDF) focus on the most Adult Deformity

  52. Slide 52: Our Vision: Global Leader in Musculoskeletal Biologics

    Our Vision: Global Leader in Musculoskeletal Biologics & Regenerative Therapies Broader Biologics s Stem cell therapy y rhGDF-5 Pain therapies Technologies Disc repair Diagnostics $1B Foundation New Bone grafting Opportunities Spine Orthopedics U.S. Dental Global Next Generation Products

  53. Slide 53: Moving Forward: Guiding Principles for Integration

    Moving Forward Guiding Principles to ensure seamless integration: 3 Maintain business momentum during the integration period 3 Understand and respect both cultures and how we operate 3 Never compromise quality or delivery of customer supply 3 Provide employees with frequent, direct and open communic

Osteotech — Merger or Acquisition (August 2010) on 6ix